Trials / Completed

CompletedNCT00745173

Study Evaluating Premarin and Bazedoxifene Potential Interaction

An Open-Label, Single/Multiple Dose Non-Randomized, 3-Period, Crossover Study To Determine The Potential Drug Interaction Of Conjugated Estrogens (CE) On Bazedoxifene In Healthy Postmenopausal Women.

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 30 (estimated)

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: Female
Age: 35 Years – 70 Years
Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics (absorption, distribution, breakdown and elimination in the body) of a single dose of bazedoxifene (BZA) 20 mg tablet when administered together with multiple doses of Premarin (conjugated estrogens or CE) to healthy postmenopausal women. Information will also be obtained regarding the safety and tolerability of this combination in healthy, postmenopausal women.

Conditions

Postmenopause

Interventions

Type	Name	Description
DRUG	Premarin

Timeline

Start date: 2008-09-01
Primary completion: 2008-10-01
Completion: 2008-10-01
First posted: 2008-09-03
Last updated: 2009-02-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00745173. Inclusion in this directory is not an endorsement.